Affordable Access

Publisher Website

Differential inhibition sensitivities of MET mutants to the small molecule inhibitor SU11274

Authors
Journal
Cancer Letters
0304-3835
Publisher
Elsevier
Publication Date
Volume
289
Issue
2
Identifiers
DOI: 10.1016/j.canlet.2009.08.017
Keywords
  • Receptor Tyrosine Kinases
  • Met
  • Point Mutations
  • Su11274
  • Drug Resistance
Disciplines
  • Biology

Abstract

Abstract Point mutations emerge as one of the rate-limiting steps in tumor response to small molecule inhibitors of protein kinases. Here we characterized the response of the MET mutated variants, V1110I, V1238I, V1206L and H1112L to the small molecule SU11274. Our results reveal a distinct inhibition pattern of the four mutations with IC 50 values for autophosphorylation inhibition ranging between 0.15 and 1.5 μM. Differences were further seen on the ability of SU11274 to inhibit phosphorylation of downstream MET transducers such as AKT, ERK, PLCγ and STAT3 and a variety of MET-dependent biological endpoints. In all the assays, H1112L was the most sensitive to SU11274, while V1206L was less affected under the used concentration range. The differences in responses to SU11274 are discussed based on a structural model of the MET kinase domain.

There are no comments yet on this publication. Be the first to share your thoughts.